Nykode Therapeutics Investor Relations Material
Latest events
Q2 2024
Nykode Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Nykode Therapeutics
Access all reports
Segment Data
Access more data
External revenue by
Geography
U.S.
Expenses by
Financials
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company based in Oslo, Norway. The company focuses on the discovery and development of novel vaccines and immunotherapies, primarily targeting cancer and infectious diseases. Nykode leverages its proprietary modular vaccine technology, which directs antigens to antigen-presenting cells, aiming to induce strong and long-lasting immune responses. Its leading product candidates include VB10.16, a therapeutic vaccine in development for human papillomavirus (HPV)-related cancers, and VB10.NEO, a cancer neoantigen vaccine, which is in clinical trials for several types of advanced tumors. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Key slides for Nykode Therapeutics
Q2 2024
Nykode Therapeutics
Q4 2023
Nykode Therapeutics
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
NYKD
Country
🇳🇴 Norway